Excessive collagen deposition may cause abnormal stiffness of the heart during hypertrophy and heart failure. The potent vasoconstrictor angiotensin II seems, via an unknown mechanism, to stimulate collagen production. This study describes the in vitro and ex vivo effects of [Sar 1 ]Ang II on collagen production by fibroblasts in culture and in beating, nonworking heart preparations. The effects of [Sar 1 ]Ang II on isolated rat hearts or rat heart fibroblasts were determined by quantifying transcript levels of collagen phenotypes I and III through videodensitometry after Northern blot analysis with specific cDNA probes (collagen [P 
B
iosynthesis of the heart's collagen matrix has been shown to be regulated under various physiological and pathologic conditions. Excessive deposition of collagen may be responsible for abnormal tissue stiffness and altered cardiac function during hypertrophy and heart failure. Workers at our laboratory have shown that during the development of hypertrophy in hypertension, the alteration of collagens and their phenotypes occurs especially during the chronic phase of hypertrophy in both humans and rats. 1 Mukherjee and Sen 2 first showed the diverse effects of antihypertensive treatment on collagen metabolism. They showed that captopril causes regression of hypertrophy associated with reduction and normalization of blood pressure and reversal of the alteration of collagen phenotypes. The molecular mechanism of such a process is not known. Butt et al 3 observed that collagen production was stimulated by some of the growth factors tested (in order of potency, transforming growth factor [TGF]-1Ͼ platelet-derived growth factorϾinsulin-like growth factorϾbasic fibroblast growth factor). Recently, evidence has been presented that defines a role of angiotensin II (Ang II), a potent vasoconstrictor, in stimulation of collagen gene expression and protein turnover in cultured cardiac fibroblasts. 4 -6 
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In addition to having a potent vasoconstrictive effect, Ang II seems to work as an autocrine/paracrine factor that regulates the growth of local tissues such as blood vessel, kidney, and heart. [7] [8] [9] [10] A close relationship has been suggested between Ang II generated at sites of injury and expression of the profibrotic cytokine represented by the TGF-␤ family of peptides. The binding of TGF-␤ 1 with its receptors on fibroblasts regulates their expression of type I collagen and tissue-induced metalloprotease and favors fibrous tissue formation. 11, 12 Recently, Kim et al 13 showed that Ang II induces collagen type I and type III mRNA expression in vivo in rats when they were infused with 200 ng Ang II ⅐ kg Ϫ1 ⅐ min
Ϫ1
. Stimulation could be observed only after 3 days of continuous infusion and gradually plateaued after 7 days. Zeydel et al 14 have shown that the deposition of type I collagen occurred only when the medium was supplemented with ascorbate and was independent of the age of the animals.
To date, no data on the effects of Ang II on collagen gene expression are available from cardiac fibroblasts of adult (Ͼ20 weeks old) rats or from isolated whole rat heart preparation. However, research on older animals is important because altered cardiac function and heart failure do not usually occur in young animals. Thus, the objectives of the present study were to examine, in parallel, the effect of [Sar 1 ]Ang II on collagen phenotypes in vitro with fibroblasts in culture and ex vivo with an isolated beating, nonworking heart preparation in 28-week-old rats. Our data showed a distinct and significant difference between ex vivo and in vitro results with fibroblasts alone in culture and combinations of fibroblasts and myocytes, the 2 major types of cells present in the heart, from both neonatal and adult rats, in which a significant stimulation of collagen transcripts was observed; this suggests the participation of myocytes in modulation of collagen production.
Methods

Materials
All tissue culture reagents used in this study were purchased from Life Technologies, Inc. All radiochemicals were obtained from DuPont-New England Nuclear. All restriction enzymes were from Boehringer Mannheim GmbH. All other chemicals and reagents were from Sigma Chemical Co. All rats used in this study were obtained from Taconic Farms. The investigation conforms with the "Guide for the Care and 
Preparation of Fibroblasts in Culture
Rat cardiac fibroblasts were isolated from normal 28-week-old Wistar-Kyoto (WKY) rats according to the method of Sil and Sen. 15 The flasks containing pure fibroblasts were then maintained at 37°C until the cells were confluent; they were subsequently passaged. The cells were used at 70% to 75% confluency and kept in serum-free medium for 24 hours before each experiment.
Beating, Nonworking Rat Heart Preparation
For the beating, nonworking heart preparation, normal 28-week-old WKY rats were heparinized with 500 U heparin and anesthetized with 20 mg/kg pentobarbital IP. The heart was taken out and washed with modified Krebs' buffer (pH 7.35) The buffer was bubbled with 95% O 2 /5% CO 2 for 30 minutes. The heart was then cannulated through the aorta and was perfused with buffer at 37°C at the rate of 135 mL/min. The heart was kept beating with a Grass electrical stimulator (frequency 8 Hz, duration 15 ms, 2.5 V).The positive and negative terminals were connected to the atria of the heart. A constant pressure of 75 mm Hg was maintained throughout the experimental period. 
Preparation of Rat Myocytes in Culture
Neonatal rat myocytes were isolated and cultured on laminin-coated glass coverslips placed in the standard 6-well plates according to the procedure described by Sil and Sen. 15 Adult myocytes were prepared on laminin-coated cover glasses according to the method of Bugaisky and Zak 16 with some modifications.
Experiment With Myocytes on Coverslips Added to Neonatal and Adult Fibroblasts in Culture
Both neonatal and adult fibroblast cells (2ϫ10 6 per well of standard 6-well plates) were incubated for 24 hours at 37°C in the absence 
Extraction of RNA and Northern Hybridization
Total RNA from fibroblast cells (in 6-well plates with or without myocytes) was isolated using the RNeasy minikit following the Qiagen protocol. RNA from each sample was then run on a 1% agarose-formaldehyde gel with DEPC-treated 1[times] MOPS as a running buffer, transblotted onto a GeneScreen membrane, and crosslinked in a UV crosslinker. The membrane was then subjected to prehybridization for 6 hours, followed by hybridization at 42.5°C for 16 hours. The hybridization of the same membrane was performed with 3 different radiolabeled probes: (1) collagen P␣ 2 r 2 type I rat cDNA probe, (2) collagen ␣ 1 type III human skin fibroblast cDNA probe, and (3) 18S rRNA oligoprobe. Hybridization and washing were performed according to Sambrook et al. 17 The membrane then was subjected to autoradiography. For estimation, the intensity of the bands was quantified with videodensitometry. The 18S RNA oligoprobe was used to normalize our results.
Quantification of Collagen
Total collagen was quantified from each rat heart by measuring hydroxyproline with a modified Stagemann procedure. 18 The amount of hydroxyproline in unknown samples was calculated with a standard curve. Collagen content was estimated by multiplying the hydroxyproline content by a factor of 8.2 and was expressed as micrograms of collagen per milligram of heart tissue.
Statistical Analysis
Results are expressed as meanϮSEM. Data were analyzed by 2-way ANOVA, and the differences between groups were determined by the least-square means test (SUPERNOVA). Differences were considered statistically significant at PϽ0.05.
Results
Effect of [Sar1]Ang II on Beating, Nonworking Heart Preparation Ex Vivo
As shown in Figure 1A , both the transcripts of collagen type I and the 5. 
Estimation of Total Collagen Ex Vivo
Ex vivo hearts compared with the control show an increase in collagen content of Ϸ33.8%, Ϸ42.06%, and Ϸ67.50% over control when perfused with 10 Ϫ12 , 10 
Effect of [Sar1]Ang II on Neonatal and Adult Rat Fibroblasts in Culture
When the neonatal and adult (28-week-old) WKY rat heart fibroblasts in serum-free media were incubated for 24 hours at 37°C in the absence (control) or presence (treated) of the 3 different concentrations of [Sar 1 ]Ang II (10
Ϫ10
, 10
Ϫ8
, and 10
Ϫ6
mol/L, respectively; nϭ5), there was no change over the control in either of the 2 collagen type I transcripts for 10
Ϫ10
or 10 Ϫ6 mol/L Ang II (Figure 3 ). There was, however, a questionable increase in both collagen type I transcripts for 10 Ϫ8 mol/L Ang II. For the same membrane, with a collagen type III cDNA probe (nϭ5), no stimulation was observed (as shown in Figure 3) . Incubation of fibroblasts for periods of 2 to 24 hours at 37°C in the presence of 10 Ϫ12 to 10 Ϫ6 mol/L [Sar 1 ]Ang II (nϭ5) also did not show any stimulation for either of the collagen transcripts (result not shown).
Effect of [Sar
]Ang II on Neonatal Rat Fibroblasts Cocultured With Neonatal or Adult Rat Myocytes
As shown in Figure 4, 
Discussion
In the present study, we demonstrated that when Ang II was added to neonatal and adult rat fibroblasts in culture in vitro in a dose-dependent fashion, no change occurred in the transcript levels of collagen type I or type III (except some questionable increase for collagen I transcripts with 10 Ϫ8 mol/L [Sar 1 ]Ang II). In contrast, in the beating, nonworking adult heart preparation, the addition of 10 Ϫ8 mol/L [Sar 1 ]Ang II showed a significant stimulation (Ϸ2-fold) of collagen mRNAs for both phenotypes (Figure 1 ). This observation suggests that the effects of Ang II in vitro and ex vivo are different and that Ang II may have an indirect effect on fibroblasts for collagen production. To understand the cellular mechanism for collagen upregulation by fibroblasts, we sought to probe into the involvement of some other cardiac cell types in the collagen gene action. When neonatal as well as adult myocytes were cocultured along with adult fibroblasts and incubated in the presence of 10 Ϫ10 mol/L [Sar 1 ]Ang II, a significant upregulation in both collagen phenotypes was observed (Figures 5 and 6 ). However, when neonatal and adult myocytes were grown on coverslips and added to neonatal fibroblasts in culture in the presence of Ang II, there was no stimulation of either collagen phenotype.
It has been suggested that excessive collagen deposition is a potential cause of stiffness of the heart during the chronic phase of hypertrophy, especially during its transition to heart failure. The molecular mechanism for this abnormal collagen formation during the chronic phase is not clearly understood. Ang II, a potent vasoconstrictor, is believed to play a role in the stimulation of collagen production in vivo. Our study shows that although Ang II had a significant effect in the stimulation of collagen production in vivo and ex vivo, it had no effect when added to pure fibroblasts in vitro except with cardiomyocytes (although fibroblasts are reported to be the sole producer for collagen in heart).
Collagen biosynthesis is regulated at different levels of transcription and translation. Type I and type III are the 2 major types of collagen present in the myocardium in both normal and diseased myocardial tissue. Thus, the quality rather than the quantity of the collagen would be an important marker to define the pathophysiology during the chronic phase of hypertrophy and heart failure. Therefore, a ratio of type I and type III is an important marker for determination of the quality of collagen and therefore prediction of the stiffness of the heart muscle. Our in vitro study shows that regardless of the time of exposure of fibroblasts alone to [Sar 1 ]Ang II, the fibroblasts did not alter collagen production, whereas a 2-hour perfusion of 10 Ϫ8 mol/L [Sar 1 ]Ang II showed significant stimulation of collagen production at the transcription as well as translation levels in the whole-heart model.
Several studies in vivo have suggested that Ang II may also be a critical factor in mediation of cardiac hypertrophy. 19 -22 These observations are consistent with, although they do not prove, the notion that Ang II may act as an endogenous growth factor for the myocardium. Thus, Ang II, directly or in combination with other growth factors, may play an important role in the development of vascular hypertrophy and elevated arterial resistance in hypertension. It is thought that many factors play a direct role in abnormal collagen deposition, such as Ang II and TGF-␤, as well as an indirect role, such as prostaglandin A 2 , bradykinin, NO, and endothelin-1, as either a stimulator or an inhibitor. 3 All of these other factors work indirectly through Ang II, and Ang II in turn stimulates collagen formation. Therefore, the results from our study are important in understanding Ang II-mediated collagen deposition because the myocyte-generated factor plays an important role in stimulation of collagen formation in conjunction with Ang II. Our preliminary data suggest that the factor from myocytes is soluble. When the supernatants from the myocyte cultures (neonatal and adult) were added to the fibroblasts, similar upregulation of collagen was observed (data not shown). Furthermore, results from the present study opened new doors to understanding the molecular mechanism for collagen production. The nature of such factors is not known, nor can we comment on the nature of the factors produced by the myocytes, but we know that identification and characterization of the factors and development of an inhibitor would be important steps in the control of the deposition of excessive fibrous tissue during the chronic phase of hypertrophy and its transition to heart failure.
Cardiac hypertrophy and heart failure remain major health problems in the United States. The chronically failing heart is associated with alteration in tissue composition, including fibrous tissue deposition that appears in both left and right ventricles. 23 Such adverse accumulation of extracellular matrix is believed to be in part responsible for myocardial stiffness and eventually affects the contractile behavior of the heart. 24 -29 Therefore, understanding the cellular and molecular mechanisms responsible for the deposition of collagen (fibrous tissue) is an essential step in designing cardioprotective agents that could prevent the deposition of collagen and, therefore, fibrosis during heart failure. 
